14 February 2017 / PARIS – Dechert LLP advised Lysogene, a biotechnology company specializing in gene therapy, on its Initial Public Offering (IPO) in compartment C of the Euronext regulated market in Paris, raising €22.6 million through capital increase. This, in combination with the 2M€ from conversion of convertible bonds subscribed by Alto Invest’s funds, will allow Lysogene to carry out a total capital increase of €24.6 million.

Lysogene will pursue its clinical trials and accelerate the development of two medicines aiming to fight against two rare diseases which attack the central nervous system from childhood and result in the patient’s premature death.

Lysogene was co-advised on this matter by Dechert LLP, with a team led by corporate partners Alain Decombe and Anne-Charlotte Rivière, with support from corporate associates Quentin Durand, Magali Stuber and Madalina Suru. Additional advisement was provided by Gide.

Read the press release in French (PDF): "Dechert conseille Lysogene dans le cadre de son introduction en bourse."